title: Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.
abstract: Voriconazole (VCZ) is frequently utilized for prevention and treatment of invasive fungal infections in peripheral stem cell transplant (PSCT) patients. We performed an open-label pharmacokinetic study to compare VCZ and N-oxide voriconazole (N-oxide VCZ) pharmacokinetics in patients pre- and post-PSCT. Ten patients completed both sampling periods. The pharmacokinetics of VCZ were unchanged; however, those of N-oxide VCZ were significantly different pre- and post-PSCT.
authors: University of Arkansas for Medical Sciences, College of Pharmacy, Department of Pharmacy Practice, Little Rock, Arkansas, USA. jamsden@butler.edu
authors: Jarrett R
authors: JR
authors: Amsden
authors: Paul O
authors: PO
authors: Gubbins
authors: Scott
authors: S
authors: McConnell
authors: Elias
authors: E
authors: Anaissie
mesh_terms: D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000517:prevention & control; D003497:Cyclic N-Oxides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D003497:Cyclic N-Oxides; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole
references: Biochem Pharmacol. 2007 Jun 15;73(12):2020-6
references: 17433262
references: J Clin Pharmacol. 2005 Dec;45(12):1373-82
references: 16291712
references: J Infect. 2007 Nov;55(5):445-9
references: 17822770
references: Curr Opin Infect Dis. 2007 Dec;20(6):579-86
references: 17975407
references: J Clin Pharmacol. 2007 May;47(5):566-78
references: 17442683
references: Drug Metab Dispos. 2003 May;31(5):540-7
references: 12695341
references: Drug Metab Dispos. 2010 Jun;38(6):923-9
references: 20304965
references: Br J Clin Pharmacol. 2008 Apr;65(4):531-9
references: 18294327
references: Drug Metab Dispos. 2010 Jan;38(1):25-31
references: 19841059
references: Antimicrob Agents Chemother. 2012 Jan;56(1):526-31
references: 22064545
references: Clin Pharmacokinet. 2006;45(7):649-63
references: 16802848
references: Xenobiotica. 2010 Oct;40(10):701-6
references: 20642349
references: Clin Infect Dis. 2012 Aug;55(3):381-90
references: 22610925
references: Drug Metab Dispos. 2008 Jun;36(6):1119-25
references: 18362161
references: J Clin Pharmacol. 2002 Apr;42(4):395-402
references: 11936564
references: Antimicrob Agents Chemother. 2009 Jan;53(1):24-34
references: 18955533
references: J Clin Pharmacol. 2008 Jan;48(1):73-84
references: 18025525
references: Clin Infect Dis. 2008 Feb 1;46(3):327-60
references: 18177225
references: J Clin Pharmacol. 2009 Feb;49(2):196-204
references: 19033450
references: J Clin Pharmacol. 2012 Feb;52(2):195-203
references: 21383338
references: Antimicrob Agents Chemother. 2002 Aug;46(8):2546-53
references: 12121931
references: Drug Metab Dispos. 2003 Jun;31(6):731-41
references: 12756205
references: Br J Clin Pharmacol. 2009 Dec;68(6):906-15
references: 20002085
references: Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1411-29
references: 21995615
references: Clin Pharmacokinet. 2002;41(12):913-58
references: 12222994